	US 12,071,623 B2
	IL-34 antisense agents and methods of using same
Francesca Viti, Salorino (CH); Marie McNulty, Dublin (IE); and Salvatore Bellinvia, Mendrisio (CH)
Assigned to Nogra Pharma Limited, Dublin (IE)
Appl. No. 18/246,845
Filed by Nogra Pharma Limited, Dublin (IE)
PCT Filed May 17, 2022, PCT No. PCT/EP2022/063300 § 371(c)(1), (2) Date Mar. 27, 2023, PCT Pub. No. WO2022/243299, PCT Pub. Date Nov. 24, 2022.
Claims priority of provisional application 63/201,887, filed on May 17, 2021.
Prior Publication US 2024/0093197 A1, Mar. 21, 2024
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01)

CPC C12N 15/1136 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3341 (2013.01)]

11 Claims

1. A polynucleotide that is complementary to IL-34 comprising a nucleotide sequence selected from the group consisting of:

a. 5′-CxTxTxTxGGGCXGCACCAGCxTxTxCx-3′ (SEQ ID NO: 40), wherein Cx is 2′-O-(2-methoxyethyl)cytidine, Tx is 2′-O-(2-methoxyethyl)thymidine, and X is 5-methylcytidine;

b. 5′-CxTxTxTGGGCXGCACCAGCTXTxCx-3′ (SEQ ID NO: 41), wherein Cx is 2′-O-(2-methoxyethyl)cytidine, Tx is 2′-O-(2-methoxyethyl)thymidine, and X is 5-methylcytidine;

c. 5′-TxCxCxAxTGACCXGGAAGCAxGxTxTx-3′ (SEQ ID NO: 42), wherein Cx is 2′-O-(2-methoxyethyl)cytidine, Ax is 2′-O-(2-methoxyethyl)adenosine, Tx is 2′-O-(2-methoxyethyl)thymidine, Gx is 2′-O-(2-methoxyethyl)guanosine, and X is 5-methylcytidine; or

d. 5′-TxCxCxATGACCXGGAAGCAGxTxTx-3′ (SEQ ID NO: 43), wherein Cx is 2′-O-(2-methoxyethyl)cytidine, Tx is 2′-O-(2-methoxyethyl)thymidine, Gx is 2′-O-(2-methoxyethyl)guanosine, and X is 5-methylcytidine;

or a pharmaceutically acceptable salt thereof.